Return to content in this issue

 

Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients

Rojas-Pérez-Ezquerra P1,2*, Crespo Quirós J1,2*, Tornero Molina P1,2, Baeza Ochoa de Ocáriz ML1,2,3, Zubeldia Ortuño JM1,2,3

1Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
2Gregorio Marañón Health Research Institute (IiGSM), Madrid, Spain
3Biomedical Research Network on Rare Diseases (CIBERER)-U761, Madrid, Spain
*These authors contributed equally to this work.

J Investig Allergol Clin Immunol 2021; Vol 31(2) : 180-181
doi: 10.18176/jiaci.0683

Key words: Anaphylaxis, COVID-19 pandemic, Polyethylene glycol, PEG 2000, mRNA vaccines

Title Type Size
doi10.18176_jiaci.0683_material-suppl_1.pdf pdf 187.02 Kb